NCT02055066View on ClinicalTrials.gov

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Cancer

Interventions

DRUG

ARGX-111

Trial Locations (2)

Unknown

Universitair Zieckenhuis Antwerpen, Antwerp

Institut Jules Bordet, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

argenx

INDUSTRY